Setiptiline

Setiptiline (brand name Tecipul), also known as teciptiline, is a tetracyclic antidepressant (TeCA) that acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). It was launched in 1989 for the treatment of depression in Japan by Mochida.[1][2]

Setiptiline
Clinical data
Trade namesTecipul
Other namesTeciptiline; delta(13b,4a),4a-Carba-mianserin; MO-8282; ORG-8282
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 2-methyl-2,3,4,9-tetrahydro-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.055.123
Chemical and physical data
FormulaC19H19N
Molar mass261.368 g·mol−1
3D model (JSmol)
SMILES
  • c42c(\C3=C(/c1ccccc1C2)CN(C)CC3)cccc4
InChI
  • InChI=1S/C19H19N/c1-20-11-10-18-16-8-4-2-6-14(16)12-15-7-3-5-9-17(15)19(18)13-20/h2-9H,10-13H2,1H3 Y
  • Key:GVPIXRLYKVFFMK-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Pharmacology

Pharmacodynamics
See also: Pharmacology of antidepressants and Tetracyclic antidepressant § Binding profiles
Setiptiline[3]
SiteKi (nM)SpeciesRef
SERT>10,000 (IC50)Rat[4]
NET220 (IC50)Rat[4]
DAT>10,000 (IC50)Rat[4]
5-HT1ANDNDND
5-HT2ANDNDND
5-HT2CNDNDND
α1NDNDND
α224.3 (IC50)Rat[5]
H1NDNDND
mAChNDNDND
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Setiptiline acts as a norepinephrine reuptake inhibitor,[4] α2-adrenergic receptor antagonist,[5] and serotonin receptor antagonist,[6] likely at the 5-HT2 subtypes, as well as an H1 receptor inverse agonist/antihistamine.[4]

Chemistry

Setiptiline has a tetracyclic structure and is a close analogue of mianserin and mirtazapine, with setiptiline being delta(13b,4a),4a-carba-mianserin, and mirtazapine being 6-azamianserin.

See also

References
  1. Buschmann, H.; Torrens, A.; Vela, J. M. (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Vol. 1. Wiley VCH. p. 248. ISBN 978-3-527-31058-6.
  2. Swiss Pharmaceutical Society, ed. (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 942. ISBN 3-88763-075-0.
  3. Roth, BL; Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  4. Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K (1986). "[Pharmacological properties of MO-8282, a novel antidepressant]". Nippon Yakurigaku Zasshi (in Japanese). 88 (4): 309–20. doi:10.1254/fpj.88.309. PMID 3792961.
  5. Mizota M, Oikawa Y, Nakayama K, Mizuguchi K, Takarada T, Kojima M, Kanehiro H, Funato H, Kayamoto M, Sato M (1986). "[Pharmacological studies of MO-8282, a new antidepressant]". Nippon Yakurigaku Zasshi (in Japanese). 88 (6): 457–66. doi:10.1254/fpj.88.457. PMID 2881854.
  6. Przegaliński E, Baran L, Siwanowicz J, Rawłów A (1986). "The lack of antidepressant properties and a potent central antiserotonin activity of Org 8282". Pol J Pharmacol Pharm. 38 (4): 377–84. PMID 3774630.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.